These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 11865330

  • 1. Biochemical parameters in the diagnosis and monitoring of neurotoxicity of antitumor cytostatics.
    Lyubimova NV, Toms MG, Shakirova IN, Gurina OI, Kushlinskii NE.
    Bull Exp Biol Med; 2001 Nov; 132(5):1093-5. PubMed ID: 11865330
    [Abstract] [Full Text] [Related]

  • 2. Cis-platinum in the treatment of testicular and other cancers.
    Williams SD, Einhorn LH.
    Adv Intern Med; 1982 Nov; 27():531-45. PubMed ID: 7041553
    [No Abstract] [Full Text] [Related]

  • 3. A Panel of Autoantibodies Against Neural Proteins as Peripheral Biomarker for Pesticide-Induced Neurotoxicity.
    El Rahman HAA, Salama M, Gad El-Hak SA, El-Harouny MA, ElKafrawy P, Abou-Donia MB.
    Neurotox Res; 2018 Feb; 33(2):316-336. PubMed ID: 28875469
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin (cis-diamminedichloroplatinum II).
    Prestayko AW, D'Aoust JC, Issell BF, Crooke ST.
    Cancer Treat Rev; 1979 Mar; 6(1):17-39. PubMed ID: 378370
    [No Abstract] [Full Text] [Related]

  • 5. Cisplatin dose intensity.
    Ozols RF.
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):22-30. PubMed ID: 2669135
    [Abstract] [Full Text] [Related]

  • 6. Heterogeneity of drug resistance in human breast and ovarian cancers.
    Kern DH.
    Cancer J Sci Am; 1998 Aug; 4(1):41-5. PubMed ID: 9467045
    [Abstract] [Full Text] [Related]

  • 7. Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor.
    Tkalia IG, Vorobyova LI, Grabovoy AN, Svintsitsky VS, Tarasova TO, Lukyanova NY, Todor IN, Chekhun VF.
    Exp Oncol; 2014 Sep; 36(3):184-90. PubMed ID: 25265352
    [Abstract] [Full Text] [Related]

  • 8. [The level of neurospecific proteins in patients with type 1 diabetes mellitus and cognitive disorders].
    Novoselova MV, Samoilova IuG, Zhukova NG.
    Klin Med (Mosk); 2014 Sep; 92(8):46-9. PubMed ID: 25790697
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity.
    Zhu J, Carozzi VA, Reed N, Mi R, Marmiroli P, Cavaletti G, Hoke A.
    Sci Rep; 2016 Jun 28; 6():28861. PubMed ID: 27350330
    [Abstract] [Full Text] [Related]

  • 13. Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
    Bespalov VG, Vyshinskaya EA, Vasil'eva IN, Semenov AL, Maidin MA, Barakova NV, Stukov AN.
    Bull Exp Biol Med; 2017 Jan 28; 162(3):383-386. PubMed ID: 28091920
    [Abstract] [Full Text] [Related]

  • 14. Clinical cancer chemotherapy aimed at potential cell regulators.
    Knock FE, Galt RM, Renaud OV, Oester YT.
    Arch Surg; 1970 Feb 28; 100(2):167-72. PubMed ID: 5460788
    [No Abstract] [Full Text] [Related]

  • 15. Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial.
    Carter SK.
    J Natl Cancer Inst; 1976 Aug 28; 57(2):235-44. PubMed ID: 794496
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J, Shi HR, Ren F, Wang JL, Wu QH, Li X, Zhang RT.
    BMC Cancer; 2017 Dec 14; 17(1):851. PubMed ID: 29241458
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy of inoperable malignancy.
    Fennelly JJ.
    Br J Surg; 1967 Oct 14; 54(10):819-24. PubMed ID: 4167308
    [No Abstract] [Full Text] [Related]

  • 18. Enzyme immunoassay of NSE and GFAP as the criterion of dynamic evaluation of the rat blood-brain barrier in perinatal hypoxic ischemic injury of the CNS.
    Chekhonin VP, Lebedev SV, Dmitrieva TB, Blinov DV, Gurina OI, Semenova AV, Volodin NN.
    Bull Exp Biol Med; 2003 Sep 14; 136(3):261-5. PubMed ID: 14666190
    [Abstract] [Full Text] [Related]

  • 19. Intrinsic cisplatin resistance in lung and ovarian cancer cells propagating in medium acutely depleted of folate.
    Whiteside MA, Piyathilake CJ, Bushell TM, Johanning GL.
    Nutr Cancer; 2006 Sep 14; 54(2):274-84. PubMed ID: 16898872
    [Abstract] [Full Text] [Related]

  • 20. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C, Yang F, Zhou C, Chen X, Han X, Liu X, Ma H, Zheng W.
    Int J Clin Exp Pathol; 2015 Sep 14; 8(3):2710-8. PubMed ID: 26045776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.